Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 2:22 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 577–600 of 3,925 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: HTN Clear all

Conditions: Diabetes, Hypertension
Interventions: Financial Incentive Group I, Financial Incentive Group II; Behavioral
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 80 Years
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Hypertension, Blood Pressure
Interventions: REDUCE-BP Intervention; Behavioral
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years to 85 Years
Enrollment: 49,210 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Patients, Resistant Hypertension
Interventions: LHW090, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 40 Years to 85 Years
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 7
States / cities: Birmingham, Alabama • North Hollywood, California • Atlantis, Florida + 4 more

Conditions: HIV Infections, Cardiovascular Diseases, Hypertension
Interventions: Indinavir sulfate, Ritonavir, Amlodipine, Diltiazem HCl; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 60 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Ends 2004
U.S. locations: 9
States / cities: San Francisco, California • Stanford, California • Denver, Colorado + 6 more

Conditions: Heart Failure
Interventions: Performance of WHEELS-I in promoting DASH/SRD adoption; Behavioral
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 45 Years and older
Enrollment: 71 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Obesity, Cardiovascular Disease, Type 2 Diabetes, Hypertension, Complication of Transplant
Interventions: Sleeve Gastrectomy; Procedure
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 75 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Ocular Hypertension Glaucoma, POAG
Interventions: DSLT; Device
Lead sponsor: The New York Eye Surgery Center; Other
Eligibility: 18 Years to 80 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Elevated Blood Pressure, Hypertension
Interventions: Boxing Training, Control flexibility; Other
Lead sponsor: University of Texas, El Paso; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 1
States / cities: El Paso, Texas

Conditions: Uncontrolled Hypertension
Interventions: Resource information, Community Health Worker (CHW) assistance, Medically-tailored Meals (MTM); Behavioral
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older
Enrollment: 224 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Neurodevelopmental Abnormality
Interventions: Aspirin, Placebo; Drug
Lead sponsor: NICHD Global Network for Women's and Children's Health; Network
Eligibility: 33 Months to 39 Months
Enrollment: 666 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 8
States / cities: Birmingham, Alabama • Denver, Colorado • Newark, Delaware + 5 more

Conditions: Aging, Arterial Stiffness, Endothelial Dysfunction, Hypertension, Cognitive Decline
Interventions: Experimental: Nitrate-containing, Placebo: Nitrate-depleted; Drug
Lead sponsor: Gary L. Pierce, PhD; Other
Eligibility: 50 Years to 79 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2024
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Pulmonary Hypertension, Interstitial Lung Disease, Lung Diseases, Vascular Diseases, Cardiovascular Diseases, Fibrosis
Interventions: Mosliciguat, Dry Powder Inhaler, Placebo; Drug · Device
Lead sponsor: Pulmovant, Inc.; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 135 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 25
States / cities: Phoenix, Arizona • Los Angeles, California • Sacramento, California + 20 more

Conditions: Primary Open Angle Glaucoma, Healthy Subjects
Interventions: SENSIMED Triggerfish; Device
Lead sponsor: Sensimed AG; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 33 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: San Diego, California

Conditions: Young Adults, Hypertension, Post-Exercise Hypotension, Circadian Rhythm
Interventions: Exercise; Behavioral
Lead sponsor: Freda Patterson; Other
Eligibility: 18 Years to 39 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Newark, Delaware

Conditions: Dry Eye Disease
Interventions: Xalatan, Travatan Z; Drug
Lead sponsor: Ophthalmic Consultants of Long Island; Other
Eligibility: 18 Years and older
Enrollment: 56 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2011
U.S. locations: 5
States / cities: East Meadow, New York • Lynbrook, New York • Rockville Centre, New York + 2 more

Conditions: Hypertension (HTN)
Interventions: Dyadic lifestyle intervention for CVD risk reduction; Behavioral
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years and older
Enrollment: 85 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Refractive Error, Glaucoma, Cataracts, Clear Lens Exchange
Interventions: Intervention; Device
Lead sponsor: Johnson & Johnson Surgical Vision, Inc.; Industry
Eligibility: Not listed
Enrollment: 1,674 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 4
States / cities: Dothan, Alabama • Bakersfield, California • Bloomington, Minnesota + 1 more

Conditions: Diabetes Mellitus
Interventions: Information and decision support for providers and patients; Other
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 18 Years and older
Enrollment: 7,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2007
U.S. locations: 1
States / cities: Burlington, Vermont

Conditions: Hypertension
Interventions: FAITH! HTN app; Behavioral
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Sarcoidosis, Precapillary Pulmonary Hypertension, Interstitial Lung Disease
Interventions: Inhaled Treprostinil; Drug
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 99 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Glaucoma
Interventions: fixed combination of brimonidine tartrate 0.2% timolol maleate 0.5% ophthalmic solution, fixed combination of dorzolamide hydrochloride timolol maleate ophthalmic solution; Drug
Lead sponsor: Allergan; Industry
Eligibility: 30 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Hypertension
Interventions: Self affirmation and positive affect induction vs. control; Behavioral
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years and older
Enrollment: 262 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2008
U.S. locations: 1
States / cities: New York, New York

Conditions: Prescription Medication Understanding
Interventions: Enhanced Label; Other
Lead sponsor: Northwestern University; Other
Eligibility: 30 Years and older
Enrollment: 850 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Hypertension
Interventions: Rheos® Baroreflex Hypertension System; Device
Lead sponsor: CVRx, Inc.; Industry
Eligibility: 21 Years to 80 Years
Enrollment: 591 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2016
U.S. locations: 42
States / cities: Birmingham, Alabama • Inglewood, California • Los Angeles, California + 38 more

Search by objective public record fields.

Way to Health, Healthy Measures

Leveraging Electronic Health Record (EHR) Tools to Reduce Health Disparities for Patients With Uncontrolled Hypertension

Safety and Efficacy Study of LHW090 in Resistant Hypertension Patients

Interactions Between HIV Protease Inhibitors and Calcium Channel Blockers

Dietary Prevention of Heart Failure in Hypertensive Metabolic Syndrome

Gastric Sleeve Pilot Study in Morbidly Obese Undergoing Liver Transplantation

Direct Selective Laser Trabeculoplasty (DSLT) for Patients With Glaucoma or Ocular Hypertension Previously Treated With SLT

Clinical Effectiveness of Boxing Training in Individuals With Elevated Blood Pressure or Stage 1 Hypertension

Sequential Multiple Assignment Randomized Trial to Reduce Food Insecurity

ASPIRIN: Neurodevelopmental Follow-up Trial

Inorganic Nitrate Supplementation on Cerebrovascular Aging and Arterial Stiffness Study

A Study of Mosliciguat in PH-ILD

Efficacy of 24-hour Intraocular Pressure Fluctuation Recording With the SENSIMED Triggerfish Contact Lens Sensor

Examining the Circadian Timing Effects of the Hypotensive Response to Exercise

Exploratory Study Comparing Signs and Symptoms in Patients With Ocular Hypertension or Glaucoma Using Xalatan R® or Travatan Z®

Assessing the Feasibility of the "Heart Care Pairs" Intervention

A Post-market Clinical Study to Collect Safety and Performance Data on Johnson & Johnson Surgical Vision Products

Vermont Diabetes Information System

HTN App for HTN Control and Cardiovascular Health Among African-Americans

Inhaled Treprostinil in Sarcoidosis Patients With Pulmonary Hypertension

Comparing Effects of Two Fixed Combinations Ophthalmic Solutions on Ocular Blood Flow

Psychosocial Determinants of Medication Adherence in Hypertensive African Americans

Enhanced Prescription Drug Label to Improve Patient Understanding and Use

Rheos® Pivotal Trial